Cancer procoagulant in human tumor cells: Evidence from melanoma patients

M. B. Donati, C. Gambacorti-Passerini, B. Casali, A. Falanga, P. Vannotti, G. Fossati, N. Semeraro, S. G. Gordon

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

It has repeatedly been proposed that fibrin plays a role in tumor growth and metastasis. Among tumor cell products or activities which may promote clot formation, cancer procoagulant (CP), a direct activator of coagulation factor X, has been suggested to be selectively associated with the malignant phenotype. We report here the enzymatic and immunological identification of this cysteine proteinase procoagulant in extracts and cells from human melanoma. CP activity was independent of both the intrinsic and extrinsic pathways of blood coagulation, using factor IX and factor VII deficient plasmas, and was inhibited by the cysteine proteinase inhibitors iodoacetamide and HgCl2. CP activity was detectable in extracts and cell suspensions from all 32 patients studied and was higher in extracts from metastases (14.8 ± 3.9 units/mg protein) than from the primary tumors (3.7 ± 1.0 units/mg protein). CP activity was not affected by an anti-apoprotein III antibody or by concanavalin A, a known inhibitor of thromboplastin. In contrast, no CP activity or antigen was detected in extracts from six benign melanocytic lesions. The procoagulant activity was dependent on factor VII and was inhibited by anti-apoprotein III antibody and by concanavalin A, properties that suggest that the procoagulant was tissue thromboplastin. These data indicate that CP can be expressed by human tumor cells and that, among melanotic lesions, its presence is associated with the malignant phenotype and its activity is particularly high in metastatic cells.

Original languageEnglish
Pages (from-to)6471-6474
Number of pages4
JournalCancer Research
Volume46
Issue number12 I
Publication statusPublished - 1986

Fingerprint

cancer procoagulant
Melanoma
Neoplasms
Factor VII
Apoproteins
Thromboplastin
Concanavalin A
Cell Extracts
Neoplasm Metastasis
Iodoacetamide
Cysteine Proteinase Inhibitors
Phenotype
Factor X
Mercuric Chloride
Factor IX
Cysteine Proteases
Antibodies
Fibrin
Suspensions
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Donati, M. B., Gambacorti-Passerini, C., Casali, B., Falanga, A., Vannotti, P., Fossati, G., ... Gordon, S. G. (1986). Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Research, 46(12 I), 6471-6474.

Cancer procoagulant in human tumor cells : Evidence from melanoma patients. / Donati, M. B.; Gambacorti-Passerini, C.; Casali, B.; Falanga, A.; Vannotti, P.; Fossati, G.; Semeraro, N.; Gordon, S. G.

In: Cancer Research, Vol. 46, No. 12 I, 1986, p. 6471-6474.

Research output: Contribution to journalArticle

Donati, MB, Gambacorti-Passerini, C, Casali, B, Falanga, A, Vannotti, P, Fossati, G, Semeraro, N & Gordon, SG 1986, 'Cancer procoagulant in human tumor cells: Evidence from melanoma patients', Cancer Research, vol. 46, no. 12 I, pp. 6471-6474.
Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G et al. Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Research. 1986;46(12 I):6471-6474.
Donati, M. B. ; Gambacorti-Passerini, C. ; Casali, B. ; Falanga, A. ; Vannotti, P. ; Fossati, G. ; Semeraro, N. ; Gordon, S. G. / Cancer procoagulant in human tumor cells : Evidence from melanoma patients. In: Cancer Research. 1986 ; Vol. 46, No. 12 I. pp. 6471-6474.
@article{96e0b07e80e5406996ee9f6bd866bf25,
title = "Cancer procoagulant in human tumor cells: Evidence from melanoma patients",
abstract = "It has repeatedly been proposed that fibrin plays a role in tumor growth and metastasis. Among tumor cell products or activities which may promote clot formation, cancer procoagulant (CP), a direct activator of coagulation factor X, has been suggested to be selectively associated with the malignant phenotype. We report here the enzymatic and immunological identification of this cysteine proteinase procoagulant in extracts and cells from human melanoma. CP activity was independent of both the intrinsic and extrinsic pathways of blood coagulation, using factor IX and factor VII deficient plasmas, and was inhibited by the cysteine proteinase inhibitors iodoacetamide and HgCl2. CP activity was detectable in extracts and cell suspensions from all 32 patients studied and was higher in extracts from metastases (14.8 ± 3.9 units/mg protein) than from the primary tumors (3.7 ± 1.0 units/mg protein). CP activity was not affected by an anti-apoprotein III antibody or by concanavalin A, a known inhibitor of thromboplastin. In contrast, no CP activity or antigen was detected in extracts from six benign melanocytic lesions. The procoagulant activity was dependent on factor VII and was inhibited by anti-apoprotein III antibody and by concanavalin A, properties that suggest that the procoagulant was tissue thromboplastin. These data indicate that CP can be expressed by human tumor cells and that, among melanotic lesions, its presence is associated with the malignant phenotype and its activity is particularly high in metastatic cells.",
author = "Donati, {M. B.} and C. Gambacorti-Passerini and B. Casali and A. Falanga and P. Vannotti and G. Fossati and N. Semeraro and Gordon, {S. G.}",
year = "1986",
language = "English",
volume = "46",
pages = "6471--6474",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12 I",

}

TY - JOUR

T1 - Cancer procoagulant in human tumor cells

T2 - Evidence from melanoma patients

AU - Donati, M. B.

AU - Gambacorti-Passerini, C.

AU - Casali, B.

AU - Falanga, A.

AU - Vannotti, P.

AU - Fossati, G.

AU - Semeraro, N.

AU - Gordon, S. G.

PY - 1986

Y1 - 1986

N2 - It has repeatedly been proposed that fibrin plays a role in tumor growth and metastasis. Among tumor cell products or activities which may promote clot formation, cancer procoagulant (CP), a direct activator of coagulation factor X, has been suggested to be selectively associated with the malignant phenotype. We report here the enzymatic and immunological identification of this cysteine proteinase procoagulant in extracts and cells from human melanoma. CP activity was independent of both the intrinsic and extrinsic pathways of blood coagulation, using factor IX and factor VII deficient plasmas, and was inhibited by the cysteine proteinase inhibitors iodoacetamide and HgCl2. CP activity was detectable in extracts and cell suspensions from all 32 patients studied and was higher in extracts from metastases (14.8 ± 3.9 units/mg protein) than from the primary tumors (3.7 ± 1.0 units/mg protein). CP activity was not affected by an anti-apoprotein III antibody or by concanavalin A, a known inhibitor of thromboplastin. In contrast, no CP activity or antigen was detected in extracts from six benign melanocytic lesions. The procoagulant activity was dependent on factor VII and was inhibited by anti-apoprotein III antibody and by concanavalin A, properties that suggest that the procoagulant was tissue thromboplastin. These data indicate that CP can be expressed by human tumor cells and that, among melanotic lesions, its presence is associated with the malignant phenotype and its activity is particularly high in metastatic cells.

AB - It has repeatedly been proposed that fibrin plays a role in tumor growth and metastasis. Among tumor cell products or activities which may promote clot formation, cancer procoagulant (CP), a direct activator of coagulation factor X, has been suggested to be selectively associated with the malignant phenotype. We report here the enzymatic and immunological identification of this cysteine proteinase procoagulant in extracts and cells from human melanoma. CP activity was independent of both the intrinsic and extrinsic pathways of blood coagulation, using factor IX and factor VII deficient plasmas, and was inhibited by the cysteine proteinase inhibitors iodoacetamide and HgCl2. CP activity was detectable in extracts and cell suspensions from all 32 patients studied and was higher in extracts from metastases (14.8 ± 3.9 units/mg protein) than from the primary tumors (3.7 ± 1.0 units/mg protein). CP activity was not affected by an anti-apoprotein III antibody or by concanavalin A, a known inhibitor of thromboplastin. In contrast, no CP activity or antigen was detected in extracts from six benign melanocytic lesions. The procoagulant activity was dependent on factor VII and was inhibited by anti-apoprotein III antibody and by concanavalin A, properties that suggest that the procoagulant was tissue thromboplastin. These data indicate that CP can be expressed by human tumor cells and that, among melanotic lesions, its presence is associated with the malignant phenotype and its activity is particularly high in metastatic cells.

UR - http://www.scopus.com/inward/record.url?scp=0022830311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022830311&partnerID=8YFLogxK

M3 - Article

C2 - 3536081

AN - SCOPUS:0022830311

VL - 46

SP - 6471

EP - 6474

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 12 I

ER -